BNP Paribas Financial Markets Purchases 168,699 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

BNP Paribas Financial Markets lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,337,470 shares of the company’s stock after buying an additional 168,699 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.12% of Teva Pharmaceutical Industries worth $29,478,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Barclays PLC increased its holdings in shares of Teva Pharmaceutical Industries by 31.7% in the 3rd quarter. Barclays PLC now owns 427,595 shares of the company’s stock valued at $7,705,000 after acquiring an additional 102,848 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Teva Pharmaceutical Industries in the third quarter worth about $50,000. Franklin Resources Inc. lifted its position in shares of Teva Pharmaceutical Industries by 141.7% during the third quarter. Franklin Resources Inc. now owns 155,091 shares of the company’s stock valued at $2,674,000 after buying an additional 90,920 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 7,458 shares of the company’s stock valued at $164,000 after buying an additional 2,297 shares in the last quarter. Finally, First Hawaiian Bank purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $723,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Barclays cut their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. Finally, Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Buy” and an average target price of $23.71.

Teva Pharmaceutical Industries Stock Up 3.0 %

Shares of Teva Pharmaceutical Industries stock opened at $18.13 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a market capitalization of $20.56 billion, a P/E ratio of -12.50, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a 50 day moving average of $15.16 and a 200 day moving average of $17.47.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. During the same quarter in the previous year, the business earned $0.48 earnings per share. The firm’s revenue was up 1.9% compared to the same quarter last year. As a group, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.